Skip to content
Screener

Twist Bioscience Corporation TWST Reportable Segment — D&A

Similar metrics at other companies

OLP
OLPXReportable Segment — D&A
$13.32M-0.4%
V2X logo
VVXReportable Segment — D&A
$28.11M+0.3%
Anterix logo
ATEXReportable Segment — D&A
$103K+35.5%
DocuSign logo
DOCUReportable Segment — D&A
$32.21M+6.1%
Chewy logo
CHWYReportable Segment — D&A
$37M+23.3%
CWA
CWANReportable Segment — D&A
$29.56M+840%

Other financials

Income statement

See full
Revenue$110.7M+19.3%
Gross profit$57.1M+24.1%
Operating income-$45.9M-10.4%
Net income-$44.0M-11.9%
EPS (diluted)-$0.71-7.6%

Balance sheet

See full
Cash & equivalents$124.9M-41.4%
Total debt$110.8M+16.3%
Total equity$455.1M+3.4%
Total assets$676.2M+13.5%

Cash flow

See full
Operating cash flow-$17.6M-35.2%
CapEx$7.9M+90.3%
Free cash flow-$25.4M-48.5%

Valuation

See full
Market cap$6.84B+338%
Enterprise value$6.83B+370%
P/S16.7×+12.4×

Profitability

See full
Gross margin52.1%+5.4pp
Operating margin-33.9%-9.9pp
Net margin-19.8%-7.7pp
FCF margin-23.2%+7.0pp

Returns & leverage

See full
Return on equity-18.2%-6.3pp
Debt / equity0.2×0.0×
Current ratio2.7×-1.8×

Where this comes from

Reported directly by Twist Bioscience Corporation in its filing.

Tagged under the XBRL concept us-gaap:DepreciationDepletionAndAmortization.

The source filing: Twist Bioscience Corporation’s 10-Q, filed May 4, 2026.

Filed
May 4, 2026, 4:28 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q1 2026
Accession
0001581280-26-000040
(in thousands)Three months ended March 31, 2026Three months ended March 31, 2025Six months ended March 31, 2026Six months ended March 31, 2025
Research and development expenses[1]17,36619,95232,71238,078
Selling, general and administrative expenses[1]59,25547,298117,03493,786
Litigation settlement costs, net of recoveries7,2057,205
Depreciation and amortization6,4146,40212,60812,784
Stock-based compensation expense18,93620,32832,20932,319
Total costs and expenses$156,578$134,353$293,176$257,711
Loss from operations$(45,863)$(41,560)$(78,763)$(76,205)
Interest income$1,710$2,801$3,885$6,041

Item 1. Financial Statements (unaudited)

FAQ

What is Twist Bioscience Corporation's reportable segment — D&A?
Twist Bioscience Corporation (TWST) reported reportable segment — D&A of $6.41M in Q1 2026.
How has Twist Bioscience Corporation's reportable segment — D&A changed year-over-year?
Twist Bioscience Corporation's reportable segment — D&A increased by 0.2% year-over-year, from $6.4M to $6.41M.
What does reportable segment — D&A mean?
Represents the systematic allocation of the cost of tangible and intangible assets over their useful lives within the reportable segment. It provides insight into the capital intensity of the segment's operations and the ongoing investment in infrastructure.

Ask your AI about Twist Bioscience Corporation's reportable segment — d&a.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude